Introduction Chronic kidney disease (CKD) is one of the consequences of human
Introduction Wide access to effective combined antiretroviral therapy (cART) and increasingly better virological and immunological control of human immunodeficiency virus 1 (HIV-1) infection results in constant improvement of the prognosis for survival of HIV-1-infected persons. Therefore, increasing attention is directed towards prevention and treatment of comorbidities and minimizing the side effects of antiretroviral drugs.
The first reports of kidney disease in patients with acquired immunodeficiency syndrome caused by HIV-1 date back to the mid-1980s [1] [2] [3] . It was proved then for the first time that HIV-1 can infect epithelial cells of the kidney [4] . Later, it was shown that there are many other infectious agents that can affect the course of renal disease, also in patients infected with HIV-1. These are hepatitis C and B viruses (HCV, HBV), parvovirus B19, cytomegalovirus, Ebstein-Barr virus, BK virus, Cryptococcus neoformans, Mycobacterium tuberculosis, and other opportunistic infections, as well as nephrotoxic drugs [5, 6] . The risk of chronic kidney disease (CKD) is associated with age, hypertension, diabetes, lower T CD4 + cell count, higher HIV viral load, and proteinuria [7] [8] [9] [10] . CKD increases the risk of progression to acquired immunodeficiency syndrome (AIDS) and death as well as the risk of side effects of antiretroviral therapy with protease inhibitors (PI) [11] .
The prevalence of renal disease in HIV-1-infected patients is difficult to estimate and depends on the diagnostic criteria for CKD. Moreover, the diagnosis of CKD, particularly at its early stages, has still unclear clinical importance [12] . Therefore, data on CKD from various studies are not uniform. The differences may result from the use of different formulas for glomerular filtration rate (GFR) estimation or from including or not proteinuria and albuminuria into diagnostic criteria.
The most commonly used method of the assessment of renal function by measuring serum creatinine is not sufficiently sensitive and specific. GFR estimation can be affected by numerous factors that influence plasma levels of creatinine and its synthesis, tubular secretion, as well as by the various factors affecting the course of laboratory testing [13] . The aim is to select the best formula that would most accurately estimate GFR for all stages of CKD, in acute kidney injury and healthy kidney, in all groups of patients, regardless of the type of kidney problem and associated diseases. In everyday practice, the most common formulas used for GFR estimation are those based on endogenous substances: creatinine and recently also on cystatin C. Experts of Kidney Disease: Improving Global Outcomes recommend the measurement of cystatin C and determination of estimated GFR (eGFR) on its basis in patients whose GFR calculated on the basis of creatinine is in the limit range for the diagnosis of CKD (45-59 ml/min/1.73 m 2 ) [13] .
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis. NO is the most potent endogenous vasodilatator and, due to its antiinflammatory and antithrombotic potential, also endogenous antiatherogenic factor [14] .
Elevated levels of ADMA were observed in numerous studies in patients with CKD, even at stage 1 of the disease [15] [16] [17] [18] [19] . In contrast, there have been no studies on the use of ADMA in the diagnosis of CKD in HIV-1-infected patients. This marker has been studied in HIV-1-infected patients mainly in terms of diagnosis of cardiovascular disease [20] [21] [22] [23] [24] [25] [26] .
Due to the complex pathology of HIV-1 infection, associated with a number of kidneydamaging agents, that occur more frequently in people living with HIV-1 than in the general population, it is important to determine the scale of the problem in this population, living in a given region, as well as the most optimal early diagnosis of the renal changes. It could have a positive impact on early intervention, closer monitoring of renal function, and adjusting antiretroviral therapy and treatment of comorbidities to kidney function.
The aim of this study was to evaluate the prevalence of the abnormalities of kidney function in patients infected with HIV-1 in the population of Lower Silesia, an administrative region of Poland, as well as to evaluate the usefulness of ADMA in the diagnosis of kidney damage in patients infected with HIV-1. We also studied the effect of some antiretroviral drugs on the parameters of renal function.
Patients and methods
The study was approved by the Bioethical Committee of the Medical University in Wroclaw (no. of consent: KB-237/2011). All study participants gave written informed consent for the participation in the study. were used. For the analysis of ADMA levels, Mann-Whitney test with Bonferroni correction was used. The dependence of the variables was assessed using the Pearson correlation coefficient r. The P values of less than 0.05 were considered statistically significant.
Calculations were performed using Statistica 10.0 for Windows (StatSoft Inc., Tulsa, Oklahoma, United States).
Results
The characteristics of the study and control group are presented in TABLE 1.
Among HIV-1-infected patients, 98 were treated with standard cART. The schedules were as follows: 65 patients were treated with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and ritonavir-boosted PI (PI/r); 25 patients, with 2 NRTI and non-nucleoside reverse transcriptase inhibitor (NNRTI); 3 individuals, with 2 NRTI and integrase inhibitor; 3 patients, with PI/r and integrase inhibitor; and 2 persons, with PI/r only.
All patients with diagnosed hypertension from the study and control groups were successfully treated with antihypertensive medications. No individual was treated with potentially antiinflammatory medications, including acetylsalicylic acid, other nonsteroid anti-inflammatory drugs, or statins.
Values of eGFR calculated according to the CKD-EPI creat in the study and control groups are presented in Table 2 . The highest values of GFR were observed in cART-naive patients and the lowest values-in the control group. Significant differences were observed between the treatment-naive group and patients on cART (P = 0.003) and between the treatment-naive patients and controls (P = 0.001). After adjustment for age, the differences of eGFR between the naive and treated groups were on the border of significance (P = 0.051).
The difference in eGFR between all HIV-1-infected patients and controls was not significant
Impaired renal function (eGFR below 60 ml/min/1.73 m 2 ) was observed only in 1 HIV-infected patient and in no control individuals. The levels of ADMA in the study group are presented in Serum ADMA levels in HIV-1-infected patients were significantly higher than those in the control group (P <0.0001). The significant differences were also noted between treatmentnaive HIV-1-infected patients and controls (P <0.0001) and between treated individuals and controls (P <0.0001). Among HIV-1-infected individuals, ADMA levels were higher in treatment-naive patients than in patients on cART; however, the difference was not significant (P = 0.14). Adjustment for significantly different variables: age, smoking status, HCV infection, and intravenous drug use did not influence the results.
We observed significant effects of potentially nephrotoxic antiretroviral drugs on higher ADMA levels compared with controls: TDF, P = 0.0001; any PI/r, P <0.0001; TDF with PI/r, P = 0.0002; ATV/r, P = 0.005; LPV/r, P <0.0001 (FIGURES 1-5). There were no significant differences in ADMA levels between patients treated with different potentially nephrotoxic drugs and in comparison with the cART regimens without the use of these drugs. ADMA levels and eGFR values were not correlated with the antiretroviral drug used (TDF, PI/r, TDF + PI/r). Serum ADMA levels were also not correlated with the mean duration of cART.
In 8 HIV-1-infected individuals, proteinuria was observed. Mean serum ADMA levels were higher in the group with proteinuria compared with individuals with normal urinalysis (0.708 vs 0.601). This difference was on the border of statistical significance (P = 0.054).
The effect of HIV infection-related factors on ADMA level was analyzed. No significant differences in ADMA levels were noted according to either current CD4 + T cell count, CD4 + nadir, or HIV-1 viral load in treatment-naive and suboptimally treated patients.
Coinfection with HCV also did not affect ADMA levels. There were no significant differences related to HIV-1 transmission route. The highest ADMA levels were observed in current smokers, and the lowest levels were noted in never-smokers; however, this difference was not significant. Other nonsignificant parameters included sex, age, body mass index (BMI), concomitant conditions (arterial hypertension and nephrolithiasis), white blood cell count, and C-reactive protein level.
Discussion CKD is currently one of the most important causes of morbidity and mortality among so called non-AIDS diseases in HIV-infected patients [27, 28] , ranking the fourth place after malignancies, cardiovascular diseases, and liver diseases, according to the EuroSIDA study [28] . The scale of the problem is not fully understood in the population of Polish HIV-1-infected patients. Among patients infected with HIV-1 in Poland, there is still a large group of drug users (many currently inactive) [29] . The drugs used by them were prepared by themselves with poppy and contained various contaminations, whose type and amount could not be determined. A large percentage of HIV-positive patients in Poland is coinfected with HCV or HBV (or both). The socioeconomic status of these patients is often low, which affects their lifestyle, diet, and treatment, similarly as in the report of Ganesan el al [30] in different populations.
The age of patients included in our study ranged from 23 to 68 years. This is the typical age of the population of people infected with HIV-1 in Poland [29] . Immunological results and HIV-1 viral loads did not differ from the data presented by authors from other Polish centers treating people with HIV infection.
ADMA plays an important role in the pathogenesis and progression of CKD and cardiovascular diseases, and this role is related to endothelial function. ADMA works by inhibiting the synthesis of NO. As an inhibitor of NO, ADMA impairs vasodilatation of capillaries. Impaired blood flow through the renal tubular capillaries causes hypoxia within the tubules and renal parenchyma [31] , which results in renal fibrosis [32, 33] . ADMA is a marker of renal impairment, independent from GFR, proteinuria, hemoglobin, and homocysteine levels [34] . Thus, ADMA allows objective assessment of renal function.
Research on ADMA is conducted in 2 directions: to assess its usefulness as a diagnostic tool and to develop drugs lowering its concentration, thereby inhibiting its pathogenic effect on endothelial function [31] . Given the numerous publications on the diagnostic role of ADMA in renal diseases, we studied it in patients infected with HIV-1, who have multiple risk factors of impaired kidney function. We did not demonstrate any significant relationship between ADMA levels and age, BMI, history of intravenous drug use, smoking, or hypertension, although other authors demonstrated a correlation between ADMA levels and hypertension [24, [32] [33] [34] [35] . HCV coinfection was noted in 39.5% of patients in the study group. This coinfection was acquired primarily by intravenous drug use. The proportion of HCV-positive patients also did not differ from data obtained in other regions of Poland. Our data showed no effect of HCV coinfection on ADMA levels.
In our study, we did not find any correlation between serum ADMA levels and eGFR in patients on cART and treatment-naive patients. We did not find differences in the concentration of ADMA in patients with eGFR values above and below 90 ml/min/1.73m 2 .
As for these latter results, we did not find literature any similar analysis in the available. We and Jang et al [24] showed that people infected with HIV had significantly higher levels of ADMA compared with uninfected individuals. On the other hand, Kurz et al [23, 37] and Baker et al [20] proved that the concentration of ADMA decreased on cART and correlated with a decrease in levels of immune activation markers. In most publications concerning ADMA and HIV infection, the impairment of endothelial function, as a result of chronic inflammation, is underlined. This impairment results in the development of subclinical atherosclerosis [24] and primary pulmonary hypertension [21] . It is believed that accumulation of ADMA as a result of chronic immune activation is associated with a predisposition to atherosclerosis [22] .
It is known that antiretroviral drugs, mainly PIs, are responsible for the development of lipodystrophy syndrome [5] . In this syndrome, body fat distribution disorders, metabolic disorders such as hyperlipidemia, insulin resistance, and glucose intolerance are present and can lead to the development of accelerated atherosclerosis [5, 38, 39] . On the other hand, ADMA is involved in the pathogenesis of atherosclerosis [20, [22] [23] [24] . 
Study limitations
Our study has several limitations. The study group was relatively small.
We did not include the parameters of chronic immune activation and microinflammation to the analysis. Data were obtained at 1 timepoint, without follow-up, so we could not show the dynamics of ADMA levels.
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